Attention-Deficit Hyperactivity Disorder

  title={Attention-Deficit Hyperactivity Disorder},
  author={Diane E. May and Professor Christopher J. Kratochvil},
Throughout this decade, there has been significant research into pharmacotherapies for attention-deficit hyperactivity disorder (ADHD). This article considers the efficacy and safety of five of the more novel long-acting pharmacological treatments recently approved by the FDA for marketing in the US for paediatric ADHD, along with an α2-adrenoceptor agonist in preparation. Reviewed treatments include the non-stimulant atomoxetine, three novel extended-release (XR) stimulant preparations… CONTINUE READING
26 Extracted Citations
143 Extracted References
Similar Papers

Citing Papers

Publications influenced by this paper.
Showing 1-10 of 26 extracted citations

Referenced Papers

Publications referenced by this paper.
Showing 1-10 of 143 references

Efficacy and safety of lisdexamfeine (LDX; NRP104) in children with attention-deficit hyperactivity disorder: a phase 3, randomized, multicenter, double-blind, parallel-group study

  • J Biederman, S Krishnan, Y Zhang
  • Clin Ther
  • 2007
Highly Influential
9 Excerpts

Strattera (atomoxetine hydrochloride) capsules for oral use: prescribing information [online]. Available from URL: strattera-pi.pdf

  • Eli Lilly, Company
  • 2009
Highly Influential
9 Excerpts

Vyvanse (lisdexamfetamine dimesylate) capsules: prescribing information [online]. Available from URL:

  • US Shire, Inc
  • 2009
Highly Influential
20 Excerpts

Similar Papers

Loading similar papers…